Sernova Secures Commercial Rights to Proprietary Stem Cell Derived Technologies – MarketWatch
|
Sernova Secures Commercial Rights to Proprietary Stem Cell Derived Technologies
MarketWatch "This agreement provides us with a proprietary source of stem cell derived glucose responsive therapeutic cells. When placed within Sernova's prevascularized Cell Pouch(TM), and protected locally from immune system attack, we believe that Sernova has … |
